TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02304627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin 338 (GIPET I)
Description: Each subject will be randomly allocated to a fixed treatment sequence of four single-dose administrations of oral insulin 338 in a GIPET® I tablet, administered on four separate dosing visits. The subjects will be dosed in the morning in the fasting state prior to four different post-dose fasting periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin 338 (GIPET I)
Description: Each subject will be randomly allocated to a fixed treatment sequence of four single-dose administrations of oral insulin 338 in a GIPET® I tablet, administered on four separate dosing visits. The subjects will be dosed in the morning in the fasting state prior to four different post-dose fasting periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin 338 (GIPET I)
Description: Each subject will be randomly allocated to a fixed treatment sequence of four single-dose administrations of oral insulin 338 in a GIPET® I tablet, administered on four separate dosing visits. The subjects will be dosed in the morning in the fasting state prior to four different post-dose fasting periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin 338 (GIPET I)
Description: Each subject will be randomly allocated to a fixed treatment sequence of four single-dose administrations of oral insulin 338 in a GIPET® I tablet, administered on four separate dosing visits. The subjects will be dosed in the morning in the fasting state prior to four different post-dose fasting periods.
Study: NCT02100423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: curcumin
Description: Given PO

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT04368377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban Injection
Description: Patients will receive 25 microgram per kilogram of body weight tirofiban as bolus IV injection (3 minutes) followed by continuous infusion at a rate of 0,15 microgram/kg//minute for 48 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Patients will receive a loading dose of clopidogrel 300 mg PO, followed by 75mg daily for 30 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: Patients will receive acetylsalicylic acid 250 mg IV before starting tirofiban, and this will be continued at a dose of 75mg daily for 30 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Description: Patients will receive concurrent fondaparinux 2.5mg s/c per day for the duration of the in hospital stay
Study: NCT00841412

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Intervention Group
Description: Unit staff received weekly training and feedback for 12-weeks to improve daily nutritional care processes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Intervention Group
Description: Research staff monitored this group under usual care conditions, then these units crossed over into intervention.
Study: NCT04506944

Intervention type: OTHER
Intervention: No intervention
Description: No specific exposure is explored.

Intervention type: OTHER
Intervention: No intervention
Description: No specific exposure is explored.

Intervention type: OTHER
Intervention: No intervention
Description: No specific exposure is explored.
Study: NCT00472017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vandetanib
Description: Oral vandetanib administration will start on the same day as RT. Treatment with vandetanib will extend for the entire duration of RT, and then will be continued after completion of RT for a maximum duration of 2 years.
Study: NCT01179867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Medication Reconciliation
Description: 1. At admission the community drug list will be electronically retrieved from the public drug insurance administrative databases using a real-time interface, and the admitting team/pharmacist will verify the list, adding over-the-counter medications~2. At discharge the attending physician/resident will write the discharge prescription using the discharge reconciliation module, allowing the physician to simultaneously view the validated community drug list and the hospital pharmacy drug list for the patient~3. The discharge communication module will facilitate identification and transfer of information on discontinued and changed medication to the respective dispensing pharmacies and prescribing physicians along with the reasons for these changes
Study: NCT02294669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Turris Facet Fuser
Description: Study participants will have a Turris Facet Fuser inserted into the contralateral facet joint, instead of a state of the art contralateral pedicle screw system.
Study: NCT01941381

Intervention type: PROCEDURE
Intervention: Tympanometry
Description: All patients enrolled with receive a tympanogram. There will be no difference between the follow up in the groups based on the tympanometry results. The study is simply observational

Intervention type: PROCEDURE
Intervention: Tympanometry
Description: All patients enrolled with receive a tympanogram. There will be no difference between the follow up in the groups based on the tympanometry results. The study is simply observational
Study: NCT03303053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholestyramine Powder 4g
Description: Cholestyramine powder 4g twice daily, Tablet Carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
Study: NCT01797354

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support group
Study: NCT01472900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2940 nm Er:YAG laser (DualisXS M002-2A, Fotona®, Fotona d.d, Ljubljana, Slovenia)
Description: 2 passes of 2940nm Er:YAG laser

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzoyl Peroxide gel
Description: 2.5% benzoyl peroxide gel apply twice daily on inflammatory acne on the control side of face
Study: NCT01376700

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)
Description: Intravenous infusion at a dose of 25 ± 5 IU/kg once per week. After 20 exposure days, the weekly infusions should be continued for as long as possible following the early prophylaxis period. If required by the clinical situation, dosing may be increased to twice weekly or even three times weekly after 20 exposure days, while keeping the low dose.
Study: NCT03810859

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Adults : 7 to 10 mL Childs : 2 to 4 mL
Study: NCT05188300

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Freestyle pedicled perforators propellers flaps for meningomyelocele defects
Description: Freestyle pedicled perforators propellers flaps for meningomyelocele defects reconstruction with sequential advance in perforators dissection, large number cases, and detailed successful technique.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Freestyle pedicled perforators propellers flaps for meningomyelocele defects
Description: Freestyle pedicled perforators propellers flaps for meningomyelocele defects reconstruction with sequential advance in perforators dissection, large number cases, and detailed successful technique.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Freestyle pedicled perforators propellers flaps for meningomyelocele defects
Description: Freestyle pedicled perforators propellers flaps for meningomyelocele defects reconstruction with sequential advance in perforators dissection, large number cases, and detailed successful technique.
Study: NCT02080754

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: effective sellick maneuver
Description: Sellick maneuver is applied, as originally described by Sellick et al .

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sham sellick maneuver
Description: The operator who applied the maneuver is the only person who knows the arm inclusion of the patient. Thus, he sets his fingers as described in Sellick arms without exerting pressure on the cricoid cartilage.
Study: NCT02846909

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: 400mg progesterone pessaries
Study: NCT03303053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Tablet prednisolone 30 mg daily for week 1, 20 mg daily for week 2, 10 mg daily for week 3 and 5 mg daily for week 4, Tablet carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Carbimazole 30 mg daily and propanolol 40 mg twice daily for 4 weeks
Study: NCT03785353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PNE lecture
Description: A translated (from English to Spanish) lecture on Pain Neuroscience Education
Study: NCT02620033

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga therapy
Study: NCT04504344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) - Soterix Medical Inc, 1x1 tDCS (conventional)
Description: We will compare the effects of active versus sham tDCS on quadriceps strength and corticospinal excitability in patients recovering from ACLR.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Anodal transcranial direct current stimulation (tDCS) - Soterix Medical Inc, 1x1 tDCS (conventional)
Description: We will compare the effects of active versus sham tDCS on quadriceps strength and corticospinal excitability in patients recovering from ACLR.
Study: NCT01915537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab group
Description: Infliximab with MTX treatment: Infliximab 3mg/kg at week 0, 2, 6 and then once every 8 weeks, MTX\>7.5mg per week. To observe the results at week 14, 30, 54 and 102 after 6 times IFX treatment. It recommended that continue to receiving IFX treatment after remission for a period of time in good economic condition patients while receiving MTX with HCQ or LEF in poor economic condition patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Classic DMARDs treatment group
Description: Classic DMARDs treatment: combination of 2 or 3 drugs, 2-drugs combination is MTX with LEF or Thunder God Vine, 3-drugs combination is MTX with HCQ and LEF or Thunder God Vine for total 30 weeks.~Effective dose: MTX: 10-15mg per week; LEF: 20mg per day; HCQ: 200-400 mg per day; Thunder God Vine: 40-60 mg per day; It recommended that the maintain regimen is MTX with HCQ or LEF after remission for a period of time.
Study: NCT02782351

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T
Description: Patients will be infused with autologous CAR-T infusion in a dose escalating manner.
Study: NCT02339844

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: 6 weeks of individual doses of aripiprazole
Study: NCT02748499

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Beat Accupunch (HBA) exercise program
Description: HBA has three phases and takes 40 minutes to complete.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants maintain their daily acitvities.
Study: NCT01530503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine and mitomycin
Description: oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food plus bolus IV infusion mitomycin C 6 mg/m2 day 1.~Cycles will be repeated in both arms every 3 weeks till progression, unacceptable toxicity, medical decision or patient's refusal or for a maximum of 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food.~Cycles will be repeated in both arms every 3 weeks till progression, unacceptable toxicity, medical decision or patient's refusal or for a maximum of 6 months
Study: NCT04285554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iRF System Hepatic Denervation
Description: The iRF System is a percutaneous, catheter-based device which uses RF energy to circumferentially denervate the sympathetic nerves surrounding the common hepatic artery (CHA).
Study: NCT01113840

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise classes three times per week in a controlled, supervised environment.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control group continues daily life as prior to randomization.
Study: NCT03265145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stiolto Respimat
Description: Duration - 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ICS (Inhaled Corticosteroid) (Triple therapy)
Description: Duration - 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LABA (Long-Acting Beta Agonist) (Triple therapy)
Description: Duration - 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAMA (Long-Acting Muscarinic Antagonist) (Triple therapy)
Description: Duration - 12 months
Study: NCT01941654

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: preemptive local ablative therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral TKI
Study: NCT01872975

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: regional nodal XRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: regional nodal XRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chestwall XRT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: WBI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WBI
Study: NCT02544867

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary behavior
Description: Participants were randomized to either reduce their total sitting time or increase sit-to-stand transitions. Information was provided in person, through written materials and by emails and phone calls in both conditions. Both groups received written educational materials on the dangers of excessive sitting and reviewed a generic day to illustrate how many sitting opportunities individuals face each day. During each session, the health educator also discussed the benefits of sitting less or increasing sit-to-stand transitions (depending on study condition) and brainstormed potential barriers to implementing the new behavior as well as strategies to overcome these barriers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary behavior
Description: Participants were randomized to either reduce their total sitting time or increase sit-to-stand transitions. Information was provided in person, through written materials and by emails and phone calls in both conditions. Both groups received written educational materials on the dangers of excessive sitting and reviewed a generic day to illustrate how many sitting opportunities individuals face each day. During each session, the health educator also discussed the benefits of sitting less or increasing sit-to-stand transitions (depending on study condition) and brainstormed potential barriers to implementing the new behavior as well as strategies to overcome these barriers.
Study: NCT02855879

Intervention type: OTHER
Intervention: Collection of biological data

Intervention type: OTHER
Intervention: Collection of clinical data
Study: NCT04781790

Intervention type: OTHER
Intervention: Bone Marrow Failure
Description: without interventional intervention . biological collection in the routine care Standard of care of patients with bone marrow failure.
Study: NCT02765100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline 100 mg twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline 100 mg twice a day
Study: NCT00706875

Intervention type: BEHAVIORAL
Intervention: questionnaire
Description: A patient questionnaire, which includes validated instruments. Data collection methods are as follows:~* In person at the medical appointment~* Over the telephone~* Mailed with self-addressed return envelope and prepaid postage~* E-mailed and returned by e-mail, fax or self-addressed envelope and pre-paid postage

Intervention type: BEHAVIORAL
Intervention: questionnaire
Description: A patient questionnaire, which includes validated instruments. Data collection methods are as follows:~* In person at the medical appointment~* Over the telephone~* Mailed with self-addressed return envelope and prepaid postage~* E-mailed and returned by e-mail, fax or self-addressed envelope and pre-paid postage
Study: NCT01349985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AGATE
Description: AGATE is a web-based adherence-enhancement intervention accessible via smartphone. All participants will be prescribed naltrexone, 50 mg, once daily for eight weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SASED
Description: Participants will receive SASED, a web-based alcohol and side-effects diary via smartphone. All participants will be prescribed naltrexone, 50 mg, once daily for eight weeks.
Study: NCT03291158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Subjects will be assigned into 5 cohorts of 5 subjects each, who will receive six doses of Minocin IV every 12 hours, starting on Day 1. Each dose of Minocin IV will be administered as an IV infusion over 1 hour. Subjects will be assigned to cohort based on time of bronchoalveolar lavage.
Study: NCT04605159

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV MAT
Description: One dose of RSV MAT vaccine reconstituted with NaCl solution, administered intramuscularly in the non-dominant arm at Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of placebo (lyophilized sucrose reconstituted with NaCl solution) administered intramuscularly in the non-dominant arm at Day 1.
Study: NCT05851794

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endomanometric guided LNF
Description: use of endomanometry during LNF

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic Nissen fundoplication alone
Description: laparoscopic Nissen fundoplication alone
Study: NCT01494415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel for Injection（Albumin Bound）
Description: concurrent: 60 mg/m2, IV, weekly; consolidation: 260 mg/m2, IV, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: concurrent: AUC 2, IV, weekly; consolidation: AUC 6, IV, every 3 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: thoracic radiation therapy
Description: 66 Gy in 33 fractions,both three-dimensional conformal and intensity modulated radiation therapy are allowed
Study: NCT01181440

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermagraft(R)
Description: Weekly application of Dermagraft(R) with conventional care

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional care
Description: Weekly application of conventional care
Study: NCT01101243

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Broadband UVB
Description: UVB dose: 1 SED every week
Study: NCT03047798

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mouthrinse
Description: A randomized clinical intervention study was planned with a cross-over design. The 34 subjects were randomly allocated to one of the three experimental groups: 1) the control; 2) ASM group for aqueous single-phase mouthrinse; 3) OTM group for oil-water two-phase mouthrinse.~Subjects were instructed to use the prescribed mouthrinse to gargle their mouth for one minute, twice daily for two weeks. The completion of each experiment regimen was followed by a 2-week washout period, after which the subjects of each group were permutated to the next mouthrinse trial until all three groups underwent the three mouthrinse trial regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mouthrinse
Description: A randomized clinical intervention study was planned with a cross-over design. The 34 subjects were randomly allocated to one of the three experimental groups: 1) the control; 2) ASM group for aqueous single-phase mouthrinse; 3) OTM group for oil-water two-phase mouthrinse.~Subjects were instructed to use the prescribed mouthrinse to gargle their mouth for one minute, twice daily for two weeks. The completion of each experiment regimen was followed by a 2-week washout period, after which the subjects of each group were permutated to the next mouthrinse trial until all three groups underwent the three mouthrinse trial regimen.
Study: NCT04114071

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TOSS Feasibility + Fitbit Community = Reduced Obesity in Older Black Women
Description: See arm description
Study: NCT01101243

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Broadband UVB
Description: UVB dose: 4 SED every second week

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Broadband UVB
Description: UVB dose: 1 SED every second week

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Broadband UVB
Description: UVB dose: 1 SED every month

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control group
Description: No intervention
Study: NCT01236794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Education Sessions and Youth Exercise Sessions
Description: The intervention will include a \~1-2 hour weekly education session to address the following constructs: health awareness, healthy eating, physical activity, roles and responsibilities, self-esteem, self-efficacy, diabetes knowledge, communication, and peer / family relationships. In addition to the education classes youth will participate in 3 exercise sessions per week (\~1-1.5 hrs) that will consist of individual and group physical activities to include both aerobic and resistance exercises. The exercise intensity will progressively increase over the 12-week intervention. Both the education and activity sessions will be delivered at the Lincoln Family YMCA.
Study: NCT04114071

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TOSS Feasibility + Fitbit Community = Reduced Obesity in Older Black Women
Description: See arm description
Study: NCT03267784

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allo-APZ2-DFU
Description: Suspension of ABCB5-positive mesenchymal stem cells